Operating characteristics of the standard phase I clinical trial design.

DOI10.1016/S0167-9473(98)00095-4zbMath1042.62623OpenAlexW1972747033WikidataQ127845836 ScholiaQ127845836MaRDI QIDQ1285808

Xavier Paoletti, Ethan Reiner, John O'Quigley

Publication date: 28 April 1999

Published in: Computational Statistics and Data Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/s0167-9473(98)00095-4

zbMATH Keywords

Allocation schemesPhase I trialsStandard phase I designStopping rulesUp and Down

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal stopping in statistics (62L15)

Related Items (8)

Target toxicity design for phase I dose-finding ⋮ Performance Measures in Dose‐Finding Experiments ⋮ Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Cumulative cohort design for dose-finding ⋮ Group up-and-down designs for dose-finding ⋮ A study of the probit model with latent variables in Phase I clinical trials ⋮ A conversation with Nancy Flournoy

Cites Work

• Unnamed Item
• Unnamed Item
• Unnamed Item
• Unnamed Item
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• Miscellanea. A stopping rule for the continual reassessment method
• Continual Reassessment Method: A Likelihood Approach
• A Random Walk Rule for Phase I Clinical Trials
• Small-Sample Confidence Sets for the MTD in a Phase I Clinical Trial
• A Method for Obtaining and Analyzing Sensitivity Data

This page was built for publication: Operating characteristics of the standard phase I clinical trial design.